O. Sibila (Barcelona, Spain), P. McShane (Chicago, United States of America)
Late Breaking Abstract - Airway hyperresponsiveness in bronchiectasis
M. de Koning Gans (Rotterdam, Netherlands), L. Kamphuis (Rotterdam, Netherlands), R. Hoek (Rotterdam, Netherlands), M. Bakker (Rotterdam, Netherlands), J. Aerts (Rotterdam, Netherlands), M. Van Der Eerden (Rotterdam, Netherlands)
|    |
Long term macrolide antibiotics for the treatment of bronchiectasis in adults - individual participant data meta-analysis
J. Altenburg (Amsterdam , Netherlands), J. Chalmers (Dundee, United Kingdom), M. Lonergan (Dundee, United Kingdom), L. Jayaram (Melbourne, Australia), L. Burr (Brisbane, Australia), M. Crichton (Dundee, United Kingdom), N. Karalus (Hamilton, New Zealand), M. Martin (Brisbane, Australia), S. Taylor (Adelaide, Australia), C. Wong (Auckland, New Zealand), W. Boersma (Alkmaar, Netherlands)
| |
The effect of azithromycin on sputum inflammatory markers in bronchiectasis – analysis of a randomized controlled trial
L. Terpstra (Alkmaar, Netherlands), S. Vijverberg (Amsterdam, Netherlands), Y. Sabogal Piñeros (Amsterdam, Netherlands), R. Lutter (Amsterdam, Netherlands), W. Boersma (Alkmaar, Netherlands), J. Altenbrug (Amsterdam, Netherlands)
| |
A point of care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation
A. Shoemark (Dundee, United Kingdom), E. Cant (Dundee, United Kingdom), L. Carreto (Amadora, Portugal), A. Smith (Dundee, United Kingdom), M. Oriano (Milan, Italy), H. Keir (Dundee, United Kingdom), L. Perea (Barcelona, Spain), E. Canto (Barcelona, Spain), L. Terranova (Milan, Italy), S. Vidal (Barcelona, Spain), K. Moffitt (Belfast, United Kingdom), S. Aliberti (Milan, Italy), O. Sibila (Barcelona, Spain), J. Chalmers (Dundee, United Kingdom)
| |
Long-term efficacy of a home-based airway clearance programme to improve cough severity in patients with bronchiectasis:a randomised controlled trial>
B. Herrero Cortina (Zaragoza, Spain), M. San Miguel-Pagola (Zaragoza, Spain), M. Francín-Gallego (Zaragoza, Spain), J. Sáez-Pérez (Zaragoza, Spain), E. Polverino (Barcelona, Spain)
|  |
Determinants of survival in the European Bronchiectasis Registry(EMBARC)
S. Aliberti (Milan, Italy), R. Menendez (Valencia, Spain), F. Blasi (Milano, Italy), F. Ringshausen (Hannover, Germany), A. De Soyza (Newcastle upon Tyne, United Kingdom), M. Vendrell (Girona, Spain), P. Goeminne (Leuven, Belgium), E. Polverino ( Barcelona, Spain), W. Boersma ( Alkmaar, Netherlands), C. Haworth ( Cambridge, United Kingdom), M. Murris ( Toulouse, France), K. Dimakou (Athens, Greece), A. Hill ( Edinburgh, United Kingdom), M. Loebinger (London, United Kingdom), A. Torres (Barcelona, Spain), T. Welte (Hannover, Germany), R. Wilson (London, United Kingdom), S. Elborn (London, United Kingdom), J. Chalmers (Dundee, United Kingdom)
| |
High Efficacy of High-dose Nitric Oxide and its Synergistic Effect with Antibiotics against Mycobacterium Abscessus
T. Chau (Bethesda, MD, United States of America), K. Blade (Bethesda, MD, United States of America), J. Da Silva (Bethesda, MD, United States of America), A. Ghaffari (Garden City, NY, United States of America), A. Zelazny (Bethesda, MD, United States of America), K. Olivier (Bethesda, MD, United States of America)
| |
Durability of culture conversion in patients receiving Amikacin Liposome Inhalation Suspension (ALIS) for treatment-refractory Mycobacterium avium complex lung disease (MAC-LD) in the CONVERT study
D. Griffith (Tyler, United States of America), R. Thomson (Brisbane, Australia), D. Addrizzo-Harris (New York, United States of America), S. Field (Calgary, Canada), J. Van Ingen (Nijmegen, Netherlands), C. Coulter (Brisbane, Australia), K. Mange (Bridgewater, United States of America), J. Nezamis (Bridgewater, United States of America), K. Winthrop (Portland, United States of America)
| |